GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 05:27:31 2024-06-03 am EDT 5-day change 1st Jan Change
1,604 GBX -9.18% Intraday chart for GSK plc -7.71% +10.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
News Highlights : Top Company News of the Day - Monday at 5 AM ET DJ
GSK Shares Plunge After Delaware Ruling on Zantac DJ
GSK vows to appeal adverse Delaware court ruling on Zantac AN
Stocks up amid slew of manufacturing PMIs AN
London stocks open nearly 1% higher, eye European rate cut; GSK slumps RE
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward RE
FTSE 100 seen up; GSK defends ranitidine cancer claim AN
European shares kick-start week higher, focus on ECB rate verdict RE
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases MT
GSK's Blenrep Combination Reduce Risk Of Disease Progression, Death By Nearly 50% RE
Gsk PLC - Statement Zantac (Ranitidine) Litigation RE
GSK Says Belantamab Mafodotin Combination Reduced Risk Of Disease Progression Or Death By Nearly 50% In Relapsed/Refractory Multiple Myeloma RE
GSK - MEDIAN PFS NOT YET REACHED AT 21.8 MONTHS MEDIAN FOLLOW-UP… RE
GSK- DREAMM-8 PHASE III TRIAL SHOWED STATISTICALLY SIGNIFICANT A… RE
GSK - BELANTAMAB MAFODOTIN COMBINATION REDUCED RISK OF DISEASE P… RE
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Delaware judge lets more than 70,000 Zantac lawsuits go forward RE
GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal RE
US FDA approves Moderna's RSV vaccine, its second marketed product RE
Goldman Sachs Starts GSK With Neutral Rating, $47 Price Target MT
Goldman Sachs Initiates GlaxoSmithKline with Neutral Rating MT
Jefferies and UBS cut Anglo American AN
Dr Martens cuts payout as profit plummets AN
GSK : Upgraded to Neutral by Goldman Sachs ZD
US nears deal to fund Moderna's bird flu vaccine trial, FT reports RE
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
17.66 GBP
Average target price
20.26 GBP
Spread / Average Target
+14.69%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. Hansoh Pharmaceutical Grants GSK Subsidiary International Marketing License for HS-20089